	US 11,884,711 B2
	Fusion proteins of GDF15 and use thereof
Yuanyuan Zhang, Beijing (CN); Wei Guo, Beijing (CN); Xinyu Zhao, Beijing (CN); Haixia Zou, Beijing (CN); Yaoguang Jin, Beijing (CN); Xu Chen, Beijing (CN); and Peng Zhai, Beijing (CN)
Assigned to BEIJING QL BIOPHARMACEUTICAL CO., LTD., Beijing (CN)
Filed by BEIJING QL BIOPHARMACEUTICAL CO., LTD., Beijing (CN)
Filed on Sep. 26, 2022, as Appl. No. 17/935,134.
Application 17/935,134 is a continuation of application No. PCT/CN2021/126453, filed on Oct. 26, 2021.
Claims priority of application No. PCT/CN2020/124031 (WO), filed on Oct. 27, 2020.
Prior Publication US 2023/0130599 A1, Apr. 27, 2023
Int. Cl. C07K 14/495 (2006.01); A61P 3/04 (2006.01); C07K 16/18 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 14/495 (2013.01) [A61P 3/04 (2018.01); C07K 16/18 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/569 (2013.01); C07K 2317/92 (2013.01); C07K 2319/31 (2013.01)]

23 Claims

1. A fusion polypeptide comprising, from N terminus to C terminus, a serum albumin binding single domain antibody, a polypeptide linker and a GDF15:

wherein the single domain antibody comprises a VHH domain, wherein the VHH domain comprises a complementarity determining region 1 (CDR1) comprising the sequence of SEQ ID NO: 1, a CDR2 comprising the sequence of SEQ ID NO: 2, and a CDR3 comprising the sequence of SEQ ID NO: 3; and

wherein the polypeptide linker has a length of 40-80 amino acid residues, wherein the polypeptide linker comprises an amino acid sequence selected from the group consisting of SEQ NOs: 48-49 and 61.